कृपया अन्य खोज का प्रयास करें
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
John Thomas | 65 | 2002 | Non-Employee Independent Director |
Mary Mirabelli | 66 | 2021 | Non-Employee Independent Director |
James Lee Tyree | 70 | 2012 | Lead Independent Director |
Thomas J. Herzog | - | - | Member of Clinical Advisory Board |
Robert W. Holloway | - | - | Member of Clinical Advisory Board |
Alberto A. Mendivil | - | - | Member of Clinical Advisory Board |
John W. Smither | 70 | 2023 | Director |
Alan B. Forsythe | - | 2023 | Member of Clinical Advisory Board |
Robert L. Coleman | 62 | - | Member of Clinical Advisory Board |
David M. O’Malley | - | - | Member of Clinical Advisory Board |
Thomas Zindrick | 64 | 2014 | Chairman, CEO & President |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है